NSAID‑Induced Gastropathy: Risk Assessment and Prevention

Mechanism of Injury

• The severity of gastrointestinal toxicity correlates with the anti‑inflammatory potency of the NSAID; high‑potency agents (e.g., piroxicam) cause more ulceration than lower‑potency agents (e.g., ibuprofen). 1

Risk Stratification

• Prior peptic ulcer disease, especially with complications, is the strongest risk factor for NSAID‑induced gastrointestinal complications. 1, 2
• A history of ulcer bleeding or perforation confers a 2‑ to 4‑fold increased risk of NSAID‑related GI events. 3, 4
• Patients with multiple risk factors have an annual complication rate approaching 18 %. 1
• High‑risk patients (≥ 3 risk factors or concomitant aspirin, anticoagulants, steroids) have an annual complication rate of 7.6‑8.6 %. 1
• Combined NSAID + aspirin use raises the relative risk of GI complications > 10‑fold compared with non‑users. 3, 4
• Moderate‑risk patients (1‑2 risk factors) have an annual complication rate of ≈ 2 %. 1
• Low‑risk patients (no risk factors) have an annual complication rate of 0.8 %. 1
• Advancing age increases risk linearly by about 4 % per year. 3, 5
• Presence of cardiovascular disease adds to GI risk. 1, 2
• Concomitant low‑dose aspirin (≤ 325 mg), other antiplatelet agents, corticosteroids, or warfarin increase NSAID‑related GI risk. 1, 3, 4
• High NSAID doses or simultaneous use of multiple NSAIDs further increase risk. 3, 4, 5
• Helicobacter pylori infection raises the risk of NSAID‑induced GI complications by 2‑ to 4‑fold. 1, 2

Clinical Impact

• NSAID use is associated with a 5‑ to 6‑fold higher relative risk of serious gastrointestinal complications, accounting for up to 100,000 hospitalizations and ≈ 16,500 deaths annually in the United States. 3, 4, 5, 7
• NSAIDs are the leading cause of bleeding peptic ulcers; > 90 % of such ulcers involve NSAID or aspirin use. 3, 4, 7
• Approximately 16 % of clinically significant NSAID‑related GI events occur in the lower gastrointestinal tract (small intestine and colon). 3, 4, 5
• Up to 25 % of chronic NSAID users experience upper GI adverse effects. 1, 2

Prevention Strategies

Low‑Risk Patients (no risk factors)

• Use the least ulcerogenic NSAID (ibuprofen) at the lowest effective dose for the shortest duration; gastro‑protective medication is not required. 1, 2

Moderate‑Risk Patients (1‑2 risk factors)

• Prescribe the least ulcerogenic NSAID plus either a proton‑pump inhibitor (PPI), misoprostol, or a COX‑2 selective inhibitor. 1, 2
• Standard‑dose PPIs significantly reduce both gastric and duodenal ulcer incidence. 8
• Misoprostol 200 µg three to four times daily reduces gastric ulcer risk by ~74 % and duodenal ulcer risk by ~53 %, but gastrointestinal side‑effects limit tolerability. 8
• H₂‑receptor antagonists reduce duodenal ulcers only and do not provide adequate gastric protection. 8

High‑Risk Patients (≥ 3 risk factors or concomitant aspirin, steroids, anticoagulants)

• With concomitant corticosteroids: a COX‑2 selective inhibitor alone is recommended. 1, 2
• With concomitant warfarin: combine a COX‑2 selective inhibitor with misoprostol. 1, 2
• Aspirin may diminish or abolish the gastro‑protective benefit of COX‑2 inhibitors; therefore, additional gastro‑protection (e.g., PPI) should be considered. 3, 4, 5, 7

Very‑High‑Risk Patients (history of ulcer complications)

• Avoid NSAIDs whenever possible; if NSAID therapy is unavoidable, use a COX‑2 selective inhibitor together with a PPI and/or misoprostol. 1, 2
• In high‑risk patients, omeprazole combined with diclofenac achieved recurrent bleeding rates comparable to celecoxib 200 mg twice daily. 8

Role of Helicobacter pylori Testing and Eradication

• All patients requiring regular NSAID therapy should be tested for H. pylori infection because the infection raises complication risk 2‑ to 4‑fold. 1, 2
• Eradication of H. pylori reduces the incidence of peptic ulcer disease in patients initiating NSAID therapy. 8
• In patients with a prior ulcer history who need NSAIDs or aspirin, H. pylori eradication alone is insufficient; concurrent gastro‑protective therapy is mandatory. 8, 6
• Omeprazole is more effective than H. pylori eradication alone in preventing recurrent ulcer bleeding among naproxen users. 8

Gastroprotective Medications

Proton‑Pump Inhibitors

• In high‑risk NSAID users, PPIs reduce the relative risk of upper GI bleeding by approximately 75‑85 %. 8, 6
• Long‑term PPI therapy has a low overall side‑effect profile, although emerging data suggest possible associations with pneumonia and hip fracture that require further confirmation. 8, 9
• Gastro‑protection with PPIs does not eliminate risk, especially in very‑high‑risk patients. 7

COX‑2 Selective Inhibitors

• COX‑2 selective inhibitors provide superior gastrointestinal safety compared with non‑selective NSAIDs in high‑risk patients. 8
• High doses of COX‑2 inhibitors (e.g., celecoxib 400 mg twice daily) are associated with a dose‑related increase in cardiovascular events such as stroke, myocardial infarction, sudden cardiac death, and heart failure. 3
• Certain non‑selective NSAIDs (ibuprofen, indomethacin, naproxen) may attenuate the cardioprotective effect of aspirin therapy. 3, 4, 5, 7

Critical Pitfalls

• Poor adherence to gastro‑protective therapy (partial or non‑adherence in > 33 % of patients) raises the relative risk of adverse GI events by 4‑ to 6‑fold. 8
• Concurrent use of multiple NSAIDs, including over‑the‑counter products, should be avoided. 3, 4
• H₂‑receptor antagonists should not be used as sole gastro‑protective agents because they do not prevent gastric ulcers. 8
• Relying only on H. pylori eradication in patients with prior ulcer disease is inadequate; additional gastro‑protection is required. 8, 6
• Antisecretory co‑therapy does not clearly prevent lower gastrointestinal tract complications from NSAIDs. 8

Alternative Analgesic Approaches

• The most effective and cost‑saving strategy to prevent NSAID‑related gastrointestinal complications is to avoid NSAIDs altogether when possible. 1, 2
• Acetaminophen should be considered first‑line for degenerative arthritis or non‑inflammatory pain conditions. 1, 2
• When NSAID therapy is unavoidable, prescribe the lowest effective dose for the shortest possible duration. 3, 4, 5, 7